Canada Approves the Use of Covifenz

Current Context: Canada has approved the use of Covifenz.

• The Covifenz is the world’s first plant-derived Covid-19 vaccine.
• It is jointly developed by Medicago Inc. and GlaxoSmithKline Plc.
• The vaccine dose can be given to adults between 18 to 64 age.
• It is made from plant-based proteins and makes use of Glaxo’s adjuvant that contains DL-alpha-tocopherol, squalene, polysorbate 80, phosphate-buffered saline.
• It also includes potassium phosphate monobasic anhydrous, anhydrous sodium chloride, sodium phosphate dibasic anhydrous, and water for injection.
• The company used living plants as bioreactors to produce a particle that mimics the target virus. Further, the virus-like particles were developed by undergoing various processes like synthesis, infiltration, incubation, harvest, and purification.
• Static Part: 
• Capital of Canada: Ottawa
• Currency of Canada: Canadian dollar